BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1197 related articles for article (PubMed ID: 25970800)

  • 1. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
    Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
    J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics.
    Ritchlin CT; Stahle M; Poulin Y; Bagel J; Chakravarty SD; Kafka S; Srivastava B; Langholff W; Gottlieb AB
    BMC Rheumatol; 2019; 3():52. PubMed ID: 31799498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
    J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
    J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
    Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Singh S; Kalb RE; de Jong EMGJ; Shear NH; Lebwohl M; Langholff W; Hopkins L; Srivastava B; Armstrong AW
    Am J Clin Dermatol; 2018 Dec; 19(6):879-886. PubMed ID: 30267377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
    JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious infections among a large cohort of subjects with systemically treated psoriasis.
    Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
    J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
    Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
    J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
    Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
    Papp KA; Strober B; Augustin M; Calabro S; Londhe A; Chevrier M;
    J Drugs Dermatol; 2012 Oct; 11(10):1210-7. PubMed ID: 23134986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
    Fiorentino D; Ho V; Lebwohl MG; Leite L; Hopkins L; Galindo C; Goyal K; Langholff W; Fakharzadeh S; Srivastava B; Langley RG
    J Am Acad Dermatol; 2017 Nov; 77(5):845-854.e5. PubMed ID: 28893407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
    Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
    Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Shalom G; Naldi L; Lebwohl M; Nikkels A; de Jong EMGJ; Fakharzadeh S; Goyal KG; Srivastava B; Langholff W; Galindo C; Cohen AD
    J Dermatolog Treat; 2019 Sep; 30(6):534-539. PubMed ID: 29619848
    [No Abstract]   [Full Text] [Related]  

  • 20. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
    J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.